Endocrine oncology

Utility of Ultrasound Surveillance for Thyroid Cancer in Children

ThyroidPublished Retrospective cohort study

Authors' conclusion

In pediatric DTC patients with excellent response to initial therapy, the utility of serial US surveillance is limited by the low risk of SDN and frequent false-positive US findings. In children with indeterminate RTT, SDN occurs in a significant proportion and may be detected by US or by abnormal Tg/TgAb levels.

Study context

Population
Pediatric patients (<19 years) with differentiated thyroid cancer (DTC) diagnosed 1998–2022, after thyroidectomy ± radioactive iodine, with excellent or indeterminate 1-year response to therapy (RTT)
Participants
112 patients
Exposure
Excellent vs indeterminate 1-year response to therapy
  • Excellent RTTn = 61
  • Indeterminate RTTn = 51
Outcome
Subsequent diagnosis of residual/recurrent structural disease in the neck (SDN), in relation to US and Tg/TgAb findings at 1 year

Main finding

As reported in the abstract

SDN during follow-up · median follow-up 6.4 years (IQR 3.8-8.9)

Excellent RTT

0

events

Indeterminate RTT

17.6%

9 of 51

Observational data: associations, not effects.

Further findings

False-positive indeterminate or abnormal US finding (excellent RTT)
29.5% · 18 of 61

Detection of structural disease in the neck (SDN) (indeterminate RTT)

SDN detected by US
7/9 (77.8%)
SDN detected by I-123 scan but not US, both with abnormal Tg/TgAb
2 (22.2%)
SDN detectable by Tg/TgAb
7/9 (77.8%)

Surveillance US and fine-needle aspiration (FNA)

Surveillance neck US performed
683
US per patient per year, mean ± SD
1.0 ± 0.4
FNA performed
17/112 (15.2%)
FNA diagnosing SDN
6 patients
FNA without SDN diagnosis
11/112 (9.8%)

Original publication

Utility of Ultrasound Surveillance for Thyroid Cancer in Children. Thyroid. Published 31 January 2025. doi:10.1089/thy.2024.0624

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.